• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Edgewise Therapeutics (EWTX) Undervalued After Positive FDA Feedback For EDG 7500?

    Simply Wall St·11/07/2026 01:22:17
    Listen to the news

    Edgewise Therapeutics (EWTX) just cleared a meaningful regulatory hurdle. The FDA gave positive End of Phase 2 feedback for EDG-7500, and the business has now submitted its STRATUS-HCM Phase 3 protocol.

    Investors have reacted quickly to the FDA update, with Edgewise Therapeutics posting a 1-day share price return of 15.87% and lifting its 7-day share price return to 15.78%. The year-to-date share price return of 89.64% sits alongside a 3-year total shareholder return of about 7x, which indicates momentum that recent earnings and regulatory progress appear to have reinforced.

    Scan beyond Edgewise Therapeutics and check a curated 19 high quality undiscovered gems that could be setting up for their own catalyst driven re-ratings.

    Bulls point to Edgewise Therapeutics’ regulatory win and sharp share price move as proof the story is working. Bears see froth after a 7x three year run. Which side does today’s valuation actually support?

    Most Popular Narrative: 17% Undervalued

    Edgewise Therapeutics closed at $45.04 against a widely followed fair value estimate of $54, which frames today’s rally as only part of the story rather than the destination.

    The main thing that has to go right is that EDG-7500 and EDG-15400 convert encouraging HCM and HFpEF data into successful Phase 3 programs that can address the large pool of symptomatic and currently under treated patients.

    The current valuation implies that the market is not fully reflecting the potential multi billion dollar HCM opportunity, the Servier transaction proceeds and the possibility that EDG-7500 becomes a key therapy without echo based titration or a REMS.

    See why 1 investors see Edgewise Therapeutics as 17% undervalued.

    Result: Fair Value of $54 (UNDERVALUED)

    Still, the story around Edgewise Therapeutics can change quickly if EDG-7500 stumbles in Phase 3 or if heavy R&D spend keeps losses elevated longer than analysts expect.

    Find out about the key risks to this Edgewise Therapeutics narrative.

    Next Steps

    Momentum cuts both ways for Edgewise Therapeutics, with clear risks on one side and meaningful potential on the other, so move quickly and pressure test the full picture for yourself with 4 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond Edgewise Therapeutics?

    If Edgewise Therapeutics has sharpened your focus on catalysts and valuation, now is the moment to widen your watchlist before the next moves get crowded.